This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
-
Novartis Investigative Site, Birmingham, Alabama, United States, 35244
Novartis Investigative Site, Los Angeles, California, United States, 90056
Novartis Investigative Site, Miami, Florida, United States, 33144
Novartis Investigative Site, Atlanta, Georgia, United States, 30342
Novartis Investigative Site, Macon, Georgia, United States, 31217
Novartis Investigative Site, Brighton, Massachusetts, United States, 02135
Novartis Investigative Site, Troy, Michigan, United States, 48084
Novartis Investigative Site, Saint Joseph, Missouri, United States, 64506
Novartis Investigative Site, Arlington, Texas, United States, 76011
Novartis Investigative Site, Cypress, Texas, United States, 77433
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 100 Years
ALL
No
Novartis Pharmaceuticals,
2028-11-27